Agenus and Zydus Finalize $141m Immunotherapy Collaboration Deal

Agenus and Zydus Lifesciences have completed a $141m strategic collaboration to accelerate the global development and potential commercialization of their botensilimab and balstilimab (BOT/BAL) immunotherapy combination program. The deal secures funding and sustained biologics manufacturing capacity in the US for Agenus and provides Zydus with exclusive rights to develop and commercialize BOT/BAL in Sri Lanka and India. Agenus is eligible for a 5% royalty on net sales from these markets and has initiated the global BATTMAN Phase III trial.